Table 3.
Rank order (decreasing) of the incidence of male lung cancer (10 countries) compared to the rank order (decreasing) of antibiotics with suspected “promoter” effect and the increasing (reverse) rank order of the suspected “inhibitor” effect of antibiotics. Of the first ten countries with the highest incidence rate of male lung cancer, nine countries can be found among the highest consumption figures of “promoter” antibiotics (exception: Poland). Seven countries with the lowest consumption figures of “inhibitor” antibiotics, are among the first high incidence rate of male lung cancer (exception: Hungary, Lithuania, Estonia)
| Incidence of Lung Cancer (Male) in Decreasing Rank Order | Rank Order (Decreasing) of Antibiotics with Possible “Promoting” Effect on the Development of Lung Cancer | ||||||
|---|---|---|---|---|---|---|---|
| Countries | New Cases/100,000 Inhabitants 2018 | Countries | J01CA + J01CR (%) | Countries | J01D (%) | Countries | J01F (%) |
| Hungary | 111.6 | Spain | 49.07 | Greece | 24.59 | Greece | 27.75 |
| Greece | 99 | Italy | 41.99 | Malta | 23.24 | Austria | 26.71 |
| Slovakia | 79.7 | France | 41.6 | Cyprus | 21.53 | Slovakia | 22.06 |
| Poland | 78.5 | Romania | 41.32 | Romania | 19.03 | Italy | 21.78 |
| Belgium | 78.1 | Lithuania | 40.22 | Luxembourg | 18.62 | Hungary | 20.77 |
| Latvia | 77.6 | Portugal | 39.57 | Croatia | 17.72 | Malta | 20.58 |
| Lithuania | 77 | Belgium | 38.31 | Slovakia | 16.87 | Czech Rep | 19.89 |
| Estonia | 76.3 | Latvia | 37.31 | Germany | 16.82 | Estonia | 19.39 |
| Croatia | 75.6 | Croatia | 36.28 | Bulgaria | 14.71 | Slovenia | 19.39 |
| France | 74.2 | Cyprus | 34.93 | Hungary | 14.28 | Germany | 19.02 |
| Incidence of Lung Cancer (Male) in Decreasing Rank Order | Rank Order (Increasing) of Antibiotics with Possible “Inhibitor” Effect on the Development of Lung Cancer | ||||||
| Countries | New cases/100,000 inhabitants 2018 | Countries | J01CE + J01CF (%) | Countries | J01A (%) | ||
| Hungary | 111.6 | Italy | 0.12 | Ireland | 2.8 | ||
| Greece | 99 | Cyprus | 0.43 | Slovenia | 4.06 | ||
| Slovakia | 79.7 | Malta | 0.66 | Romania | 4.1 | ||
| Poland | 78.5 | Latvia | 0.95 | Portugal | 5.74 | ||
| Belgium | 78.1 | Luxembourg | 1.29 | Spain | 5.79 | ||
| Latvia | 77.6 | Belgium | 1.6 | Malta | 6.53 | ||
| Lithuania | 77 | Greece | 1.63 | Croatia | 7.9 | ||
| Estonia | 76.3 | Spain | 1.86 | Greece | 8.26 | ||
| Croatia | 75.6 | France | 2.17 | Slovakia | 8.56 | ||
| France | 74.2 | Poland | 2.32 | Austria | 9.21 | ||
J01CA—broad-spectrum, beta-lactamase sensitive penicillin; J01R—broad-spectrum penicillin with beta-lactamase inhibitors; J01D—cephalosporin; J01F—macrolide; J01CE—narrow-spectrum, beta-lactamase-sensitive penicillin; J01CF—narrow-spectrum, beta-lactamase-resistant penicillin; J01A—tetracycline.